Unit of Respiratory Medicine, Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark.
Department of Respiratory Medicine, Næstved Hospital, Næstved, Denmark.
Respiration. 2019;98(5):428-433. doi: 10.1159/000501834. Epub 2019 Sep 27.
In patients with suspected or proven lung cancer, assessment of regional nodal and distant metastases is key before treatment planning. By introducing the endobronchial ultrasound (EBUS)-guided scope into the esophagus and stomach (EUS-B), liver lesions and celiac nodes can be visualized. To date, the utility of EUS-B in diagnosing liver lesions and retroperitoneal lymph nodes is unknown.
To assess the feasibility, safety, and diagnostic yield of sampling of liver lesions and retroperitoneal nodes by EUS-B fine-needle aspiration (FNA) in a lung cancer staging setting.
Consecutive patients suspected of lung cancer in 2 Danish centers between 1 January 2015 and 31 December 2017 were included retrospectively when a lesion in the liver or a retroperitoneal lymph node was visualized and biopsied with EUS-B-FNA.
23 left liver lobe lesions and 19 retroperitoneal lymph nodes were sampled by EUS-B-FNA. Sensitivity and diagnostic yield of sampled liver lesions were 86 and 83%, respectively. In 19/23 patients, there was a cytopathological diagnosis of malignancy. Sensitivity and diagnostic yield from retroperitoneal lymph node samples were 83 and 63%, respectively. In 10/19 patients, the diagnosis was malignancy. No complications were observed.
EUS-B-FNA enables safe sampling of left liver lobe lesions and retroperitoneal lymph nodes. EUS-B should be considered as a minimally invasive technique to provide tissue proof of distant metastases lung cancer patients.
在疑似或确诊肺癌患者中,在制定治疗计划之前,评估区域淋巴结和远处转移至关重要。通过将支气管内超声(EBUS)引导的内镜引入食管和胃(EUS-B),可以观察到肝脏病变和腹腔干淋巴结。迄今为止,EUS-B 诊断肝脏病变和腹膜后淋巴结的效用尚不清楚。
评估 EUS-B 引导下细针抽吸(FNA)在肺癌分期中对肝脏病变和腹膜后淋巴结进行采样的可行性、安全性和诊断率。
回顾性纳入 2015 年 1 月 1 日至 2017 年 12 月 31 日期间在丹麦 2 个中心疑似肺癌的连续患者,当在肝脏或腹膜后淋巴结中观察到病变并用 EUS-B-FNA 进行活检时。
23 个左肝叶病变和 19 个腹膜后淋巴结用 EUS-B-FNA 取样。取样肝脏病变的敏感性和诊断率分别为 86%和 83%。在 23 例患者中,有 19 例有恶性肿瘤的细胞学诊断。腹膜后淋巴结样本的敏感性和诊断率分别为 83%和 63%。在 19 例患者中,有 10 例诊断为恶性肿瘤。未观察到并发症。
EUS-B-FNA 可安全地对左肝叶病变和腹膜后淋巴结进行取样。EUS-B 应被视为一种微创技术,可为肺癌患者提供远处转移的组织证据。